Publication | Closed Access

Safety and efficacy of pioglitazone for the delay of cognitive impairment in people at risk of Alzheimer's disease (TOMMORROW): a prognostic biomarker study and a phase 3, randomised, double-blind, placebo-controlled trial

Neurodegenerative DiseasesNeuropsychologyAlzheimer's DiseaseDementiaVascular DementiaPlacebo-controlled TrialSocial SciencesNeurochemical BiomarkersNeurologyNeuroscienceAging-associated DiseaseMedicineTreatmentPhase 3